Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
23
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
Health economic evaluation identifies, measures, values, and compares alternative strategies to efficiently allocate scarce resources. The validity, methodological quality, and generalizability of economic evaluations must be assessed, as poorly designed studies can lead to incorrect conclusions. Therefore, this study aimed to evaluate the quality and characteristics of published economic evaluations done in Ethiopia, using the Quality of Health Economics Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. Various electronic databases were searched using different keywords. We included only original studies conducted in Ethiopia that evaluated the cost and consequences of at least two health interventions. Abstracts, treatment guidelines, reviews, expert opinions, and studies that included other countries were excluded. Two reviewers independently evaluated each study using the QHES and CHEERS instruments and any disagreements were then resolved by a third reviewer. The study included 21 studies published between 2002 and 2021. HIV was the most frequently evaluated medical condition, examined in four (19.06%) of the 21 studies. Seventeen of the studies (80.95%) compared healthcare services or programs, while the other four examined pharmaceutical products. Cost-utility analysis was the economic evaluation technique used in 14 studies (66.67%). Of the studies that disclosed their funding sources, foreign institutions were involved in funding 71.43% of them. Disability-adjusted life-year (DALY) was an outcome metric used in nine (42.86%) studies. The average QHES score of the studies was 82%. Fourteen studies had QHES scores of ≥75% and two had scores of <50%. The studies evaluated using the CHEERS instrument ranged in quality from 42.9% to 92.9%, with an average of 78.23%. Our study revealed that Ethiopia lacks health economic evaluations, particularly on non-communicable diseases. This indicates that the economic evaluation of healthcare interventions in Ethiopia is still in its early stages. Additionally, Ethiopian institutions have played a very limited role in funding research, highlighting the importance of active participation from local institutions.
Sections du résumé
BACKGROUND
BACKGROUND
Health economic evaluation identifies, measures, values, and compares alternative strategies to efficiently allocate scarce resources. The validity, methodological quality, and generalizability of economic evaluations must be assessed, as poorly designed studies can lead to incorrect conclusions. Therefore, this study aimed to evaluate the quality and characteristics of published economic evaluations done in Ethiopia, using the Quality of Health Economics Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments.
METHODOLOGY
METHODS
Various electronic databases were searched using different keywords. We included only original studies conducted in Ethiopia that evaluated the cost and consequences of at least two health interventions. Abstracts, treatment guidelines, reviews, expert opinions, and studies that included other countries were excluded. Two reviewers independently evaluated each study using the QHES and CHEERS instruments and any disagreements were then resolved by a third reviewer.
RESULT
RESULTS
The study included 21 studies published between 2002 and 2021. HIV was the most frequently evaluated medical condition, examined in four (19.06%) of the 21 studies. Seventeen of the studies (80.95%) compared healthcare services or programs, while the other four examined pharmaceutical products. Cost-utility analysis was the economic evaluation technique used in 14 studies (66.67%). Of the studies that disclosed their funding sources, foreign institutions were involved in funding 71.43% of them. Disability-adjusted life-year (DALY) was an outcome metric used in nine (42.86%) studies. The average QHES score of the studies was 82%. Fourteen studies had QHES scores of ≥75% and two had scores of <50%. The studies evaluated using the CHEERS instrument ranged in quality from 42.9% to 92.9%, with an average of 78.23%.
CONCLUSION
CONCLUSIONS
Our study revealed that Ethiopia lacks health economic evaluations, particularly on non-communicable diseases. This indicates that the economic evaluation of healthcare interventions in Ethiopia is still in its early stages. Additionally, Ethiopian institutions have played a very limited role in funding research, highlighting the importance of active participation from local institutions.
Identifiants
pubmed: 37624553
doi: 10.1007/s41669-023-00433-y
pii: 10.1007/s41669-023-00433-y
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
877-886Informations de copyright
© 2023. The Author(s).
Références
Zhao Y, Feng HM, Qu J, Luo X, Ma WJ, Tian JH. A systematic review of pharmacoeconomic guidelines. J Med Econ. 2018;21(1):85–96.
pubmed: 28959910
doi: 10.1080/13696998.2017.1387118
World Health Organization. Delivering quality health services: a global imperative for universal health coverage. World Health Organization. 2019. https://www.who.int/publications/i/item/9789241513906 .
Smithard DG, Haslam J. COVID-19 pandemic healthcare resource allocation, age and frailty. New Bioeth. 2021;27(2):127–32.
pubmed: 33913400
doi: 10.1080/20502877.2021.1917101
Goldstuck ND. Healthcare in low-resource settings: the individual perspective. Healthc Low-resour Settings. 2014;2(2):4572.
doi: 10.4081/hls.2014.4572
Farid S, Elmahdawy M, Baines D. A systematic review on the extent and quality of Pharmacoeconomic publications in Egypt. Clin Drug Investig. 2019;39(2):157–68.
pubmed: 30460486
doi: 10.1007/s40261-018-0730-5
Farrell TW, Francis L, Brown T, et al. Rationing limited healthcare resources in the COVID-19 era and beyond: ethical considerations regarding older adults. Am Geriatr Soc. 2020;68(6):1143–9.
doi: 10.1111/jgs.16539
Tran BX, Nong VM, Maher RM, Nguyen PK, Luu HN. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One. 2014;9(8):1–12.
Dang A, Likhar N, Alok U. Importance of economic evaluation in health care: an Indian perspective. Value Heal Reg Issues. 2016;9(6):78–83.
doi: 10.1016/j.vhri.2015.11.005
Alzarea AI, Khan YH, Alanazi AS, Butt MH, Almalki ZS, Alahmari AK, et al. Barriers and facilitators of pharmacoeconomic studies: a review of evidence from the middle eastern countries. Int J Environ Res Public Health. 2022;19(13):1–18.
doi: 10.3390/ijerph19137862
Eljilany I, El-Dahiyat F, Curley LE, Babar ZUD. Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries. Expert Rev Pharmacoeconomics Outcomes Res. 2018;18(4):403–14.
doi: 10.1080/14737167.2018.1479254
Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):1–10.
doi: 10.18549/PharmPract.2021.1.2302
Pandey P, Pandey RD, Shah V. Evaluation of quality of pharmacoeconomic studies in Asia-Pacific Region and identification of influencing variables. Value Heal Reg Issues. 2018;15:70–5.
doi: 10.1016/j.vhri.2017.07.007
Marshall DA, Donald F, Lacny S, Reid K, Bryant-Lukosius D, Carter N, et al. Assessing the quality of economic evaluations of clinical nurse specialists and nurse practitioners: a systematic review of cost-effectiveness. NursingPlus Open. 2015;1:11–7.
doi: 10.1016/j.npls.2015.07.001
Henrikson N, Skelly A. Economic studies part 2: evaluating the quality. Evid Based Spine Care J. 2013;4(1):2–5.
pubmed: 24436693
pmcid: 3699241
doi: 10.1055/s-0033-1341594
Hoomans T, Evers SMAA, Ament AJHA, Hübben MWA, Van Der Weijden T, Grimshaw JM, et al. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. Value Heal. 2007;10(4):305–16.
doi: 10.1111/j.1524-4733.2007.00175.x
Husereau D, Drummond M, Augustovski F, De B-G, Briggs AH. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(23):4–11.
Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.
pubmed: 14613362
Gebretekle GB, Mariam DH, Mac S, Abebe W, Alemayehu T, Degu WA, et al. Cost-utility analysis of antimicrobial stewardship programme at a tertiary teaching hospital in Ethiopia. BMJ Open. 2021;11(12):1–10.
doi: 10.1136/bmjopen-2020-047515
Belay YB, Ali EE, Chung KY, Gebretekle GB, Sander B. Cost-utility analysis of Dolutegravir-versus Efavirenz-based regimens as a first-line treatment in adult HIV/AIDS patients in Ethiopia. PharmacoEconomics Open. 2021;5(4):655–64.
pubmed: 34133017
pmcid: 8611130
doi: 10.1007/s41669-021-00275-6
Johns B, Asfaw E, Wong W, Bekele A, Minior T, Kebede A, et al. Assessing the costs and effects of antiretroviral therapy task shifting from physicians to other health professionals in Ethiopia. J Acquir Immune Defic Syndr. 2014;65(4):140–7.
doi: 10.1097/QAI.0000000000000064
Olsen M, Norheim OF, Memirie ST. Reducing regional health inequality: a sub-national distributional cost-effectiveness analysis of the community-based treatment of childhood pneumonia in Ethiopia. Int J Equity Health. 2021;20(1):1–10.
doi: 10.1186/s12939-020-01328-8
Driessen J, Olson ZD, Jamison DT. Comparing the health and social protection effects of measles vaccination strategies in Ethiopia: an extended cost-effectiveness analysis. Soc Sci Med. 2015;139:115–22.
pubmed: 26189009
doi: 10.1016/j.socscimed.2015.06.018
Yigezu A, Alemayehu S, Hamusse SD, Ergeta GT, Hailemariam D, Hailu A. Cost-effectiveness of facility-based, stand-alone and mobile-based voluntary counseling and testing for HIV in Addis Ababa, Ethiopia. Cost Eff Resour Alloc. 2020;18(1):1–12.
doi: 10.1186/s12962-020-00231-x
Shimels T, Bilal AI. Hemodialysis or transplantation for Ethiopia: a cost-utility analysis. Ann Adv Biomed Sci. 2019;2(1):1–10.
Tesfaye A, Fiseha D, Assefa D, Klinkenberg E, Balanco S, Langley I. Modeling the patient and health system impacts of alternative xpert
Strand KB, Chisholm D, Fekadu A, Johansson KA. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health Policy Plan. 2016;32:504–13.
doi: 10.1093/heapol/czv093
Kebede TT, Svensson M, Addissie A, Trollfors B, Andersson R. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation. BMC Public Health. 2019;19(1078):1–12.
Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, et al. A cost-effectiveness analysis of rivaroxaban compared to warfarin for Deep Vein Thrombosis (DVT) treatment in Ethiopia. Clin Outcomes Res. 2021;13:821–34.
doi: 10.2147/CEOR.S327868
Enden MR, Tolla MT, Norheim OF. Providing universal access to modern contraceptive methods: an extended cost-effectiveness analysis of meeting the demand for modern contraception in Ethiopia. Soc Sci Med. 2021;281:1–10.
doi: 10.1016/j.socscimed.2021.114076
Eregata GT, Hailu A, Stenberg K, Johansson KA, Norheim OF, Bertram MY. Generalised cost-effectiveness analysis of 159 health interventions for the Ethiopian essential health service package. Cost Eff Resour Alloc. 2021;19(1):1–13.
doi: 10.1186/s12962-020-00255-3
Mathewos B, Owen H, Sitrin D, Cousens S, Degefie T, Wall S, et al. Community-Based Interventions for Newborns in Ethiopia (COMBINE): cost-effectiveness analysis. Health Policy Plan. 2017;32:21–32.
doi: 10.1093/heapol/czx054
Memirie ST, Tolla MT, Desalegn D, Hailemariam M, Norheim OF, Verguet S, et al. A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia. Health Policy Plan. 2019;34(4):289–97.
pubmed: 31106346
pmcid: 6661540
doi: 10.1093/heapol/czz034
Assebe LF, Belete WN, Alemayehu S, Asfaw E, Godana KT, Alemayehu YK, et al. Economic evaluation of Health Extension Program packages in Ethiopia. PLoS ONE. 2021;16(2):1–16.
doi: 10.1371/journal.pone.0246207
Hailu A, Lindtjørn B, Deressa W, Gari T, Loha E, Robberstad B. Cost-effectiveness of a combined intervention of long-lasting insecticidal nets and indoor residual spraying compared with each intervention alone for malaria prevention in Ethiopia. Cost Eff Resour Alloc. 2018;16(1):1–17.
doi: 10.1186/s12962-018-0164-1
Bekele M, Norheim OF, Hailu A. Cost-effectiveness of Saxagliptin compared with Glibenclamide as a second-line therapy added to metformin for type 2 diabetes Mellitus in Ethiopia. MDM Policy Pract. 2021;6(1):1–12.
Zegeya EA, Tushune K, Abdosh B, Chrispim PPM. Cost effectiveness analysis of PMTCT service delivery modalities in Addis Ababa (using decision models). SSRN Electron J. 2012. https://doi.org/10.2139/ssrn.2180719 .
doi: 10.2139/ssrn.2180719
Zergaw A, Mariam DH, Ali A. Cost-effectiveness analysis of health care interventions in Meskanena Mareko Wereda, Ethiopia. Ethiop J Health Dev. 2002;16(3):267–76.
doi: 10.4314/ejhd.v16i3.9794
Alemayehu S, Yigezu A, Hailemariam D, Hailu A. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia. PLoS One. 2020;15:1–13.
Toba S, Tomasini M, Yang YH. Supply chain management in hospital: a case study. Calif J Oper Manag. 2008;6(1):49–55.
Mauskopf JA. Why study pharmacoeconomics? Expert Rev Pharmacoeconomics Outcomes Res. 2001;1(1):1–3.
doi: 10.1586/14737167.1.1.1
Min C, Xue M, Haotian F, Jialian L, Lingli Z. An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics. PLoS One. 2021;16(2):1–13.
Zegeye EA, Mbonigaba J, Kaye SB, Wilkinson T. Economic evaluation in Ethiopian healthcare sector decision making: perception, practice, and barriers. Appl Heal Econ Heal Policy. 2017;15(1):33–43.
doi: 10.1007/s40258-016-0280-z
Jiang S, Ma X, Desai P, Yang L, Rascati K. A systematic review on the extent and quality of pharmacoeconomic publications for China. Value Heal Reg Issues. 2014;3(1):79–86.
doi: 10.1016/j.vhri.2014.02.010
Hoque ME, Khan JAM, Hossain SSA, Gazi R, Rashid HA, Koehlmoos TP, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Eff Resour Alloc. 2011;9(1):12.
pubmed: 21771343
pmcid: 3158529
doi: 10.1186/1478-7547-9-12
Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr Ther Res - Clin Exp. 2008;69(3):268–85.
pubmed: 24692805
pmcid: 3969967
doi: 10.1016/j.curtheres.2008.06.005
Ma H, Jian W, Xu T, He Y, Rizzo JA, Fang H. Quality of pharmacoeconomic research in China: a systematic review. Medicine. 2016;95(41):1–8.
doi: 10.1097/MD.0000000000005114